Answers are grounded in this paper and cite their sources.
EBV-associated HD and NHL show type II latency expressing subdominant EBV antigens such as LMP2, which may serve as targets for immunotherapy. Previously, we used polyclonal EBV-specific CTL in patients with relapsed EBV +ve HD and saw 2 CRs and 1 PR in 11 patients. We now hypothesize that CTL specifically targeting LMP2 might have greater efficacy. LMP2-CTL were generated using dendritic cells and lymphoblastoid cell lines which had been genetically modified to overexpress LMP2 by transduction with an Ad5f35LMP2 vector.
No takes yet. Share an insight, caveat, or question.
Bollard et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: